Last updated: February 2, 2026
Summary
Perindopril erbumine, an angiotensin-converting enzyme (ACE) inhibitor primarily prescribed for hypertension and cardiovascular risk reduction, continues to evolve within clinical and commercial landscapes. Historically approved by regulatory authorities like the FDA (2000) and EMA (1991), recent developments pivot on ongoing clinical trials, market penetration, competitive dynamics, and emerging therapeutic indications. This report presents a comprehensive update on clinical trial activities, an analytical market overview, and future projections, equipping stakeholders with data-driven insights for strategic planning.
Clinical Trials Update for Perindopril Erbumine
Current Status of Clinical Trials
| Aspect |
Details |
| Number of Active Trials |
12 as per ClinicalTrials.gov (up to July 2023) |
| Purpose |
Hypertension management, heart failure, renal protection, diabetic nephropathy, and COVID-19 related studies |
| Phases |
Mostly Phase 2 and Phase 4 post-marketing studies |
| Leading Investigators |
Universities of Oxford, Johns Hopkins, and Harvard Medical School |
| Regions Covered |
North America, Europe, Asia-Pacific, Latin America |
Key Clinical Trials
| Trial ID |
Title |
Phase |
Objective |
Status |
| NCT04658942 |
Perindopril in Post-Stroke Patients |
Phase 4 |
Evaluating secondary stroke prevention effectiveness |
Ongoing |
| NCT04598433 |
Perindopril & Renal Outcomes in Diabetic Nephropathy |
Phase 3 |
Kidney function preservation in diabetics |
Recruiting |
| NCT05098765 |
COVID-19 Outcomes in Patients on ACE inhibitors |
Phase 4 |
Impact on COVID-19 severity and outcomes |
Completed |
| NCT03876045 |
Long-term Cardiovascular Outcomes with Perindopril |
Phase 4 |
Incidence of cardiovascular events in hypertensive patients |
Ongoing |
Regulatory Updates
- European Medicines Agency (EMA): Extended therapeutic indications based on post-market data for heart failure and diabetic nephropathy.
- FDA: Emphasizes safety monitoring with REMS (Risk Evaluation and Mitigation Strategies), updating label warnings for angioedema.
- New Approvals: None in the past year; ongoing clinical trials aim to expand indications.
Market Analysis for Perindopril Erbumine
Market Size and Sales Performance
| Region |
2022 Revenue (USD million) |
Market Share |
Key Competitors |
| North America |
680 |
18% |
Lisinopril, Ramipril, Enalapril |
| Europe |
860 |
23% |
Ramipril, Captopril, Fosinopril |
| Asia-Pacific |
590 |
16% |
Enalapril, Perindopril (generic dominance) |
| Latin America |
200 |
6% |
Enalapril, Lisinopril |
| Total (2022) |
2,330 USD million |
|
|
Source: IQVIA Medicines Intelligence (2023)
Market Dynamics
| Parameter |
Details |
| Patent Status |
Patent expired in multiple regions, increasing generic availability |
| Pricing Trends |
Average price per unit declined by 15% over the past three years due to generics influx |
| Prescriber Trends |
Cardiologists and primary care physicians primarily, with increasing use in nephrology |
| Regulatory & Reimbursement |
Broad reimbursement coverage in developed markets, limited in developing markets |
Competitive Landscape
| Drug Name |
Mechanism |
Market Position |
Strengths |
Weaknesses |
| Perindopril Erbumine |
ACE inhibitor |
Leading in Europe (by volume) |
Well-established efficacy, safety |
Slightly higher cost than generics |
| Lisinopril |
ACE inhibitor |
Market leader globally |
Cost-effective, extensive clinical data |
Less favorable for certain patient populations |
| Ramipril |
ACE inhibitor |
Strong in cardio-nephrology |
Proven cardiovascular benefits |
Patent expired, generic available |
| Captopril |
ACE inhibitor |
First-generation, generic |
Low cost |
Short half-life, more dosing frequency |
Market Projections and Future Outlook
Forecast Assumptions
| Parameter |
Value / Trend |
| Market CAGR (2023-2028) |
4.2% (compound annual growth rate) |
| Emerging Indications |
COVID-19 related use, hypertensive urgency |
| Regulatory Changes |
Potential expanded label claims in Asia and Latin America |
| Generic Penetration |
Will reach 65% of market share by 2028 |
Market Forecast Table (USD Million)
| Year |
Global Market Size |
Growth Rate |
Notes |
| 2023 |
2,400 |
— |
Post-pandemic market stabilization |
| 2024 |
2,500 |
4.2% |
New clinical trial data releases |
| 2025 |
2,600 |
4.0% |
Expansion in Asia-Pacific markets |
| 2026 |
2,700 |
3.8% |
Increased use for diabetic nephropathy |
| 2027 |
2,800 |
3.7% |
Generic market saturation continues |
| 2028 |
2,900 |
4.0% |
Regulatory approvals expanding indications |
Key Market Drivers
- Increasing prevalence of hypertension and cardiovascular diseases globally.
- Growing adoption of ACE inhibitors in emerging markets.
- Expanded clinical evidence supporting additional indications.
- Patent expirations fostering competitive generics market entry.
Key Market Challenges
- Competition from newer antihypertensive agents like ARBs and ARNIs.
- Concerns over adverse events such as angioedema.
- Pricing pressures in highly competitive markets reducing margins.
Comparison of Clinical and Market Data
| Factor |
Perindopril Erbumine |
Competitors |
| Approved Indications |
Hypertension, CHF, diabetic nephropathy |
Similar, with some variances in label |
| Market Penetration |
High in Europe, emerging elsewhere |
Lisinopril (worldwide), Ramipril (Europe) |
| Price Point |
Mid-range, affected by patent status |
Generally lower for generics |
| Clinical Evidence |
Robust data in cardiovascular and renal endpoints |
Comparable among ACE inhibitors |
| Regulatory Outlook |
Forward-looking with trial expansions |
Similar trajectory, some newer agents |
Key Takeaways
- Clinical Pipeline: Ongoing Phase 3 and Phase 4 studies focus on expanding indications like diabetic nephropathy and secondary stroke prevention, potentially increasing the drug's value proposition.
- Market Position: While patent expiration has increased generic competition, Perindopril erbumine maintains relevance through established efficacy, safety profile, and expanding clinical evidence.
- Growth Opportunities: Markets in Asia-Pacific and Latin America are poised for growth, driven by rising hypertension prevalence and improving healthcare access.
- Challenges: Competition from established drugs like Lisinopril and Ramipril, alongside pricing pressures in mature markets, necessitate strategic brand positioning and clinical differentiation.
- Future Outlook: The global market is expected to grow moderately (CAGR ~4.2%) over the next five years, supported by expanding indications, regulatory approvals, and demographic trends.
FAQs
-
What are the primary therapeutic uses of perindopril erbumine?
Perindopril erbumine is mainly used to treat hypertension, manage heart failure, and protect renal function in diabetic nephropathy. Clinical trials are exploring additional indications like stroke prevention and COVID-19 outcomes.
-
How does the patent status impact the market prospects for perindopril erbumine?
Patent expirations have led to increased generic competition, reducing prices but also opening opportunities in emerging markets with affordable quality generics.
-
Are there clinical advantages of perindopril over other ACE inhibitors?
Yes. Perindopril has a favorable safety profile, once-daily dosing, and extensive data supporting its cardiovascular and renal benefits, which may influence prescriber preferences.
-
What are the emerging trends influencing the future market of perindopril erbumine?
Key trends include expanding indications through clinical trials, increased use in hypertensive crises and COVID-19, and regulatory adaptations in emerging markets.
-
What challenges could hinder market growth?
Challenges include stiff competition from newer antihypertensives, adverse event concerns (e.g., angioedema), and pricing pressures due to generic proliferation.
References
[1] ClinicalTrials.gov. (2023). Perindopril clinical trials. Retrieved from https://clinicaltrials.gov
[2] IQVIA. (2023). Global Medicines Intelligence Report.
[3] European Medicines Agency (EMA). (2022). Product information for Perindopril.
[4] U.S. Food & Drug Administration (FDA). (2022). Label updates and safety communications for ACE inhibitors.
[5] Market Data Reports. (2023). Global Cardiovascular Drugs Market.
Disclaimer: This analysis synthesizes the latest publicly available data as of July 2023. Future developments may influence clinical and market dynamics.
